Avita Medical’s Recell Go mini gets FDA approval, stock rises over 6%

Investing.com — Avita Medical (NASDAQ:RCEL)’s stock saw a post-market increase of over 6% on Monday, following the company’s announcement that the US Food and Drug Administration (FDA) has given its approval to the premarket approval supplement for Recell Go mini.

This product is an addition to the firm’s skin-repair product line. The Recell Go mini is a mini disposable cartridge, specifically designed to treat smaller wounds up to 480 square centimeters.

Avita Medical (TASE:PMCN) has stated that the rollout of Recell Go mini will commence with trauma and burn centers that currently treat smaller wounds.

“The FDA approval of Recell Go mini strengthens our ability to provide clinicians with fit-for-purpose solutions that meet the diverse needs of patients with full-thickness wounds,” Jim Corbett, the Chief Executive Officer of Avita Medical said in a press release.

The company expects this rollout to begin during the first quarter of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.